MEDGENOME
Leader in Genetic Testing Services, Genomics Research and Drug Discovery Solutions
Leader in Genetic Testing Services, Genomics Research and Drug Discovery Solutions
MedGenome is a biotechnology and healthcare company founded in 2013 with a mission to enhance global health through decoding individuals' genetic information. The company operates a Next Generation Sequencing (NGS) lab in Foster City, California, US, and is a market leader in genetic diagnostic testing in India and South Asia. The recent $50.00M Series D investment on 30 August 2022 by Novo Holdings, LeapFrog Investments, and Sofina reflects investor confidence in the company's vision and capabilities. MedGenome offers over 1300 genetic tests across various disease areas and is the only NGS facility in the country validated to run the highly accurate non-invasive prenatal test (Panorama). With a dedicated team of over 700 biologists, bioinformaticians, and statisticians, MedGenome empowers clinicians, patients, and global pharma and biotech research projects with its genomics solutions.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series D | $50.00M | 3 |
|
30 Aug 2022 |
| Venture Round | INR1.23B | 1 |
|
15 Jul 2021 |
| Series D | $55.00M | 3 |
|
01 Apr 2020 |
| Venture Round | Unknown | 1 |
|
01 Jan 2019 |
| Series C | $10.00M | 3 | HDFC Standard Life Insurance, HDFC Mutual Fund +1 | 05 Mar 2018 |
No recent news or press coverage available for MEDGENOME.
We care about your data, and we'd love to use cookies make your experience better.
